Osi Pharmaceuticals, Inc.

Syntex (u.s.a.) Inc.

Agouron Pharmaceuticals, Inc.

Other

The Wistar Institute

Prosidion Limited

Cadus Pharmaceutical Corp.

Arlindo Lucas Castelhano

Bryan McKibben

David James Witter

Jian Jeffrey Chen

Andrew Philip Crew

Steven Lee Bender

An-Hu Li

Jeffrey Allen Campbell

Chris Allen Broka

Judith Gail Deal

Robert Than Hendricks

Li Qiu

Radoslaw Laufer

Melwyn A Abreo

Michael J Melnick

Colin Peter Sambrook Smith

Tao Zhang

Keith Adrian Walker

Stephen E Horne

Roland Joseph Billedeau

Arno G Steinig

Han-Qing Dong

Teng Jiam Liak

Wesley K M Chong

Zhengyu Yuan

Hanqing Dong

Eric W Collington

Garry Robert Smith

Alexander Krantz

Paul M Lieberman

Troy E Messick

Kristen Michelle Mulvihill

Chrystelle Marie Rasamison

Alun Smith

Joshua Bolger

Jian-Min Fu

Mark Joseph Mulvihill

Lawrence Emerson Fisher

Martin James Procter

Kevin James Doyle

Douglas S Werner

Keshab Sarma

Ayako Honda

Kosuke Yasuda

Matthew Colin Thor Fyfe

Neil Anthony Pegg

Keith Adrian Murray Walker

Gary Conard Visor

Shazia Sadiq

Yingchuan Sun

Wesley K Chong

Geoffrey Martyn Williams

John Fraser Keily

Anthony Innocenzo Nigro

Gary Karl Newton

Paul David Cannon

Cara Cesario

Graham Wynne

Lisa Sarah Gardner

Maseo Nawano

Saleh Ahmed

Graham Dawson

Imaad Saba

Don Smyth

Lawrence Tardibono

Hal Van Wart

Vanessa Smith

Patricia Anne Beck

Yingchaun Sun

Graham Michael Wynne

Claire Thomas

Hui Shao

Bryan Mckibben

Arno Steinig

Eric William Collington

The invention relates, in certain aspects, to developable forms of certain compounds that are useful to treat and/or prevent EBV infection and related conditions in a subject. The invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.

EBNA1 inhibitor crystalline forms, and methods of preparing and using same

Salt forms of mTOR inhibitors of the Formula (I): and methods of preparation, formulation, and use in treating disease.

mTOR inhibitor salt forms

Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R, m and J are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.

(Arylamidoaryl)squaramide compounds

Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-Oxide thereof, are useful in the treatment of cancer.

N-substituted imidazopyridine c-Kit inhibitors

Compounds of the formula and pharmaceutically acceptable salts thereof, wherein n, n, n, n, G, Q, Z, R, R, R, R, R, R, and Rare defined herein, inhibit the cytochrome PRAI enzyme and are useful for the treatment and/or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.

Naphthylene derivatives as cytochrome P450 inhibitors

The subject invention provides compounds having the structure: 

[object Object]

This invention pertains to compounds which specifically inhibit the adenosine Areceptor and the use of these compounds to treat a disease associated with Aadenosine receptors in a subject.

Compounds specific to adenosine A, receptors and uses thereof

Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.

N-substituted benzimidazolyl c-Kit inhibitors

This invention pertains to compounds having the structure: wherein which specifically inhibit the adenosine A1 and A3 receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compound.

The subject invention provides compounds having the structure: wherein Ris substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; Ris hydrogen, or a substituted or unsubstituted alkyl, &#x2014;C(O)-alkyl, &#x2014;C(O)&#x2014;O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; Ris hydrogen, or a substituted or unsubstituted alkyl, &#x2014;C(O)-alkyl, &#x2014;C(O)&#x2014;O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or Rand Rare joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present Ris oxygen; Rand Rare each independently substituted or unsubstituted alkyl, &#x2014;C(O)-alkyl, &#x2014;C(O)&#x2014;O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or RNRtogether form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl moiety containing from 1 to 6 heteroatoms;

N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors

N3-substituted imidazopyridine c-Kit inhibitors

Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, Rand J are defined herein, are useful in the treatment of cancer.

(Arylamidoaryl) cyanoguanidine compounds

Novel deazapurines are disclosed which are useful for the treatment of adenosine receptor stimulated diseases.

4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use

Growing community of inventors

New City, NY, United States of America

Arlindo Lucas Castelhano